NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

NRx Pharmaceuticals announced the pricing of an underwritten public offering of 5.7 million shares at $3.50 per share, expected to raise approximately $20 million (or $23 million with full underwriter option). The clinical-stage biopharmaceutical company plans to use net proceeds for working capital and general corporate purposes. The offering is expected to close on June 4, 2026.

06/03/2026, 8:18 AM • Benzinga

NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why

NRx Pharmaceuticals announced a proposed underwritten public offering of common stock, causing shares to plummet 19.05% to $3.74 in after-hours trading on Tuesday. The clinical-stage biopharmaceutical company, which develops treatments for CNS disorders including suicidal depression and PTSD, plans to use the net proceeds for working capital and general corporate purposes. BTIG LLC is acting as lead bookrunner for the offering.

06/03/2026, 1:46 AM • Benzinga

My Top 3 Biotech Stocks for May 2026

With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.

05/20/2026, 11:15 AM • The Motley Fool

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

NRx Pharmaceuticals reported Q1 2026 financial results showing a net loss of $1.4 million, improved from $5.5 million in Q1 2025. The company advanced its preservative-free ketamine ANDA toward FDA approval expected in Q3 2026, initiated commercial manufacturing, and received FDA clearance for a Phase 2b/3 trial of NRX-101 combined with robotic-assisted TMS. The company also won a bid to acquire Geneuro's HERV-targeting asset portfolio and expanded its HOPE Therapeutics clinic network to five locations.

05/18/2026, 7:00 AM • GlobeNewswire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

NRx Pharmaceuticals announced it will release its first quarter 2026 financial results on May 18, 2026, followed by a conference call. The clinical-stage biopharmaceutical company is developing NMDA platform-based therapeutics for CNS disorders, with NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) in development. NRX-100 has received Fast Track Designation and NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.

05/14/2026, 7:00 AM • GlobeNewswire

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

NRx Pharmaceuticals announced the appointment of Glenn Tyson as its first Chief Commercial Officer. Tyson brings 25 years of pharmaceutical industry experience and clinical background in mental health treatment. The appointment comes as NRx anticipates FDA approval of its preservative-free ketamine ANDA and prepares to submit a New Drug Application to expand ketamine labeling for depression and suicidality treatment.

04/13/2026, 7:00 AM • GlobeNewswire

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

NRx Pharmaceuticals received FDA preliminary alignment on labeling for its preservative-free ketamine generic drug application, with only minor formatting changes required. The company expects final approval under GDUFA in Summer 2026. The product addresses ketamine supply shortages and is manufactured in the US, aligning with FDA's focus on re-shoring critical drug supply elements.

04/06/2026, 7:00 AM • GlobeNewswire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

NRx Pharmaceuticals announced it will host a conference call on March 24, 2026 to report full year 2025 financial results and provide updates on its drug development programs. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) for treating suicidal depression, chronic pain, and PTSD. NRX-100 has received Fast Track Designation and NRX-101 has been awarded Breakthrough Therapy Designation.

03/19/2026, 7:00 AM • GlobeNewswire

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, announced the opening of a Palm Beach, FL clinic offering interventional psychiatry treatments including ketamine, transcranial magnetic stimulation (TMS), and hyperbaric oxygen therapy for depression and PTSD. Published results show 87% clinical response rates with their treatment protocol, and 90% return to full function when hyperbaric oxygen is added.

03/09/2026, 7:00 AM • GlobeNewswire

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

NRx Pharmaceuticals appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Prof. Brown is a leading expert in Transcranial Magnetic Stimulation (TMS) and neuroplasticity, currently serving as President of the Clinical TMS Society. He will lead efforts to advance NRx's drug development programs, particularly focusing on treating PTSD and depression in military personnel, veterans, and first responders through combination therapies including TMS and NRX-101 (D-cycloserine/lurasidone).

03/02/2026, 7:00 AM • GlobeNewswire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, acquired a strategic interest in Cohen and Associates, a premier interventional psychiatry clinic in Florida. Dr. Rebecca Cohen was appointed as HOPE's Medical Director, bringing expertise in TMS and psychiatric treatments.

10/20/2025, 8:03 AM • Benzinga